Aurinia Pharmaceuticals Stock Analysis
AUPH Stock | USD 5.03 0.06 1.18% |
Aurinia Pharmaceuticals is fairly valued with Real Value of 4.9 and Target Price of 14.0. The main objective of Aurinia Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Aurinia Pharmaceuticals is worth, separate from its market price. There are two main types of Aurinia Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Aurinia Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Aurinia Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Aurinia Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Aurinia Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Aurinia Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Aurinia Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Aurinia |
Aurinia Stock Analysis Notes
About 39.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aurinia Pharmaceuticals recorded a loss per share of 0.54. The entity had not issued any dividends in recent years. The firm had 1:50 split on the 23rd of October 2013. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 300 people. For more info on Aurinia Pharmaceuticals please contact Stephen Zaruby at 250 744 2487 or go to https://www.auriniapharma.com.Aurinia Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aurinia Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aurinia Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aurinia Pharmaceuticals generated a negative expected return over the last 90 days | |
Aurinia Pharmaceuticals has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 175.51 M. Net Loss for the year was (78.02 M) with profit before overhead, payroll, taxes, and interest of 83.38 M. | |
Aurinia Pharmaceuticals currently holds about 391.51 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
Latest headline from news.google.com: Aurinia Pharmaceuticals Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies UK |
Aurinia Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Aurinia Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aurinia Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of February 2024 Upcoming Quarterly Report | View | |
2nd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Aurinia Largest EPS Surprises
Earnings surprises can significantly impact Aurinia Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2018-11-08 | 2018-09-30 | -0.19 | -0.21 | -0.02 | 10 | ||
2016-03-18 | 2015-12-31 | -0.15 | -0.13 | 0.02 | 13 | ||
2024-02-15 | 2023-12-31 | -0.16 | -0.19 | -0.03 | 18 |
Aurinia Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aurinia Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aurinia Pharmaceuticals backward and forwards among themselves. Aurinia Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Aurinia Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | International Biotechnology Trust Plc | 2023-09-30 | 1 M | Schroder Investment Management Group | 2023-12-31 | 1 M | Susquehanna International Group, Llp | 2023-12-31 | 1 M | Balyasny Asset Management Llc | 2023-12-31 | 887 K | Tang Capital Management Llc | 2023-09-30 | 750 K | Group One Trading, Lp | 2023-12-31 | 678.8 K | Woodline Partners Lp | 2023-12-31 | 645.2 K | Citadel Advisors Llc | 2023-09-30 | 637.9 K | Jane Street Group, Llc | 2023-12-31 | 582.5 K | Armistice Capital, Llc | 2023-12-31 | 9.5 M | Blackrock Inc | 2023-12-31 | 8.9 M |
Aurinia Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 739.72 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aurinia Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Aurinia Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Aurinia Profitablity
Aurinia Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Aurinia Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Aurinia Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Aurinia Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Aurinia Pharmaceuticals' profitability requires more research than a typical breakdown of Aurinia Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.44) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.53) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.53. Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.14) | (0.15) | |
Return On Capital Employed | (0.18) | (0.19) | |
Return On Assets | (0.14) | (0.15) | |
Return On Equity | (0.21) | (0.22) |
Management Efficiency
Aurinia Pharmaceuticals has return on total asset (ROA) of (0.1052) % which means that it has lost $0.1052 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1992) %, meaning that it created substantial loss on money invested by shareholders. Aurinia Pharmaceuticals' management efficiency ratios could be used to measure how well Aurinia Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.15. The current Return On Capital Employed is estimated to decrease to -0.19. As of now, Aurinia Pharmaceuticals' Total Current Assets are increasing as compared to previous years. The Aurinia Pharmaceuticals' current Intangible Assets is estimated to increase to about 7 M, while Net Current Asset Value is forecasted to increase to (8.5 M).Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.64 | 2.51 | |
Net Current Asset Value | -8.9 M | -8.5 M | |
Tangible Asset Value | -8.7 M | -8.3 M | |
Tangible Book Value Per Share | 2.60 | 2.47 | |
Enterprise Value Over EBITDA | (18.65) | (17.72) | |
Price Book Value Ratio | 3.41 | 3.58 | |
Enterprise Value Multiple | (18.65) | (17.72) | |
Price Fair Value | 3.41 | 3.58 | |
Enterprise Value | 1.4 B | 1.5 B |
The analysis of Aurinia Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Aurinia Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Aurinia Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.379 |
Technical Drivers
As of the 24th of April, Aurinia Pharmaceuticals shows the Mean Deviation of 2.26, standard deviation of 3.9, and Risk Adjusted Performance of (0.09). Aurinia Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Aurinia Pharmaceuticals, which can be compared to its peers. Please confirm Aurinia Pharmaceuticals information ratio and potential upside to decide if Aurinia Pharmaceuticals is priced correctly, providing market reflects its regular price of 5.03 per share. Given that Aurinia Pharmaceuticals has information ratio of (0.18), we suggest you to validate Aurinia Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Aurinia Pharmaceuticals Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Aurinia Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Aurinia Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Aurinia Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aurinia Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aurinia Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aurinia Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Knappertz Volker over a month ago Acquisition by Knappertz Volker of 256892 shares of Aurinia Pharmaceuticals subject to Rule 16b-3 | ||
Scott Habig over a month ago Disposition of 15867 shares by Scott Habig of Aurinia Pharmaceuticals at 5.48 subject to Rule 16b-3 | ||
Stephen Robertson over a month ago Disposition of 57745 shares by Stephen Robertson of Aurinia Pharmaceuticals at 5.6 subject to Rule 16b-3 | ||
Peter Greenleaf over two months ago Acquisition by Peter Greenleaf of 661538 shares of Aurinia Pharmaceuticals subject to Rule 16b-3 | ||
Smith Karen L over six months ago Acquisition by Smith Karen L of 17913 shares of Aurinia Pharmaceuticals subject to Rule 16b-3 | ||
Michael Martin over a year ago Acquisition by Michael Martin of 107202 shares of Aurinia Pharmaceuticals subject to Rule 16b-3 |
Aurinia Pharmaceuticals Predictive Daily Indicators
Aurinia Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aurinia Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 24373.55 | |||
Daily Balance Of Power | (0.38) | |||
Rate Of Daily Change | 0.99 | |||
Day Median Price | 5.08 | |||
Day Typical Price | 5.06 | |||
Price Action Indicator | (0.08) | |||
Period Momentum Indicator | (0.06) | |||
Relative Strength Index | 27.49 |
Aurinia Pharmaceuticals Corporate Filings
F3 | 20th of March 2024 An amendment to the original Schedule 13D filing | ViewVerify |
F4 | 7th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 29th of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
22nd of February 2024 Other Reports | ViewVerify | |
8K | 15th of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of February 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 12th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of January 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Aurinia Pharmaceuticals Forecast Models
Aurinia Pharmaceuticals' time-series forecasting models are one of many Aurinia Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aurinia Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Aurinia Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Aurinia Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aurinia shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Aurinia Pharmaceuticals. By using and applying Aurinia Stock analysis, traders can create a robust methodology for identifying Aurinia entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.44) | (0.46) | |
Operating Profit Margin | (0.47) | (0.50) | |
Net Loss | (0.44) | (0.47) | |
Gross Profit Margin | 0.92 | 0.97 |
Current Aurinia Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aurinia analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aurinia analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
14.0 | Strong Buy | 6 | Odds |
Most Aurinia analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aurinia stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aurinia Pharmaceuticals, talking to its executives and customers, or listening to Aurinia conference calls.
Aurinia Stock Analysis Indicators
Aurinia Pharmaceuticals stock analysis indicators help investors evaluate how Aurinia Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aurinia Pharmaceuticals shares will generate the highest return on investment. By understating and applying Aurinia Pharmaceuticals stock analysis, traders can identify Aurinia Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 94.2 M | |
Common Stock Shares Outstanding | 143.2 M | |
Total Stockholder Equity | 378 M | |
Tax Provision | 947 K | |
Property Plant And Equipment Net | 116.6 M | |
Cash And Short Term Investments | 350.5 M | |
Cash | 48.9 M | |
Accounts Payable | 4.3 M | |
Net Debt | 48.7 M | |
50 Day M A | 5.4738 | |
Total Current Liabilities | 77.2 M | |
Other Operating Expenses | 258.8 M | |
Non Current Assets Total | 123.3 M | |
Forward Price Earnings | 128.2051 | |
Non Currrent Assets Other | 1.5 M | |
Stock Based Compensation | 45.3 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Aurinia Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.225 | Quarterly Revenue Growth 0.586 | Return On Assets (0.11) | Return On Equity (0.20) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.